6th May 2015 11:12
LONDON (Alliance News) - GW Pharmaceuticals PLC Wednesday said it has begun a phase two clinical trial of GWP42006 in adult patients with epilepsy.
GW is a biopharmaceutical company that aims to discover, develop and commercialise novel therapeutics from its proprietary cannabinoid product platform. GWP42006 is a non-psychoactive cannabinoid cannabidivarin extracted from cannabis plants.
"The start of this Phase 2 CBDV study represents another important milestone for GW's research in the field of epilepsy," Justin Gover, chief executive, said in a statement.
"While much of the recent attention regarding GW has been associated with our Epidiolex childhood epilepsy program which has now advanced into Phase 3 trials, we believe that CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy. GW has completed significant pre-clinical work on CBDV as well as a Phase 1 trial which demonstrated a reassuring safety profile, and we look forward to progressing this Phase 2 trial during 2015," Gover added.
Also Wednesday, GW Pharmaceuticals said it raised USD179.2 million in its offering of 1.6 million American Depositary Shares at USD112.00 each.
GW shares were up 1.3% at 604.00 pence on Wednesday.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L